Allarity Therapeutics Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments. Its current work centers on stenoparib, an investigational therapy being studied for advanced recurrent ovarian cancer, alongside its proprietary Drug Response Predictor technology, which is designed to help identify patients most likely to benefit from specific oncology drugs. The company also supports a limited portfolio of additional cancer-focused programs and companion diagnostics intended to improve treatment selection and clinical decision-making. Allarity Therapeutics operates primarily in the oncology and drug development segments, with activities in the United States and Denmark. As a specialist in biomarker-guided cancer care, the company occupies a niche role in the broader pharmaceutical market by combining therapeutic development with diagnostic tools to support more targeted treatment approaches.
Website123 E. Tarpon Ave.
Tarpon Springs, FL, 34689
United States
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that
TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, p
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP®-guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to accelerate and support U.S.
Investors talking about ALLR also mention
What share of all stock conversation is about ALLR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% -0.01 | 0% +0 | 0% +0 | 0% -0.02 |
Of the messages about ALLR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 100% +12.24 | 72.29% +52.06 | 61.93% -28.47 | 75.2% -11.86 | ||
| Bearish | 0% -12.24 | 27.71% -52.06 | 38.07% +28.47 | 24.8% +11.86 |
Of the messages about ALLR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 100% | 89.2% | 74.02% | ||
| Technical Analysis | 0% | 0% | 10.8% | 21.86% | ||
| Controversies | 0% | 0% | 0% | 1.03% | ||
| Earnings | 0% | 0% | 0% | 0.75% | ||
| Macro | 0% | 0% | 0% | 0.83% | ||
| Analysts | 0% | 0% | 0% | 1.5% |
Of the messages about ALLR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 54.29% | 76.87% | 85.99% | 91.71% | ||
| Newcomers | 45.71% | 23.13% | 14.01% | 8.29% |